197 filings
Page 3 of 10
6-K
9pk30l5olrn45 m5eyd
31 Mar 22
Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress
7:17am
POSASR
1m75z970c
31 Mar 22
Automatic shelf registration (post-effective amendment)
7:10am
6-K
d8zbsz 1iz81g
6 Jan 22
Enrollment of REDIRECT study (AFM13-202) is completed; topline clinical readout expected in 2H 2022
7:23am
6-K
9at2g4
9 Dec 21
Current report (foreign)
7:30am
6-K
7af qn2bi
22 Nov 21
Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate
7:55am
6-K
rj33cnup
10 Nov 21
Current report (foreign)
8:12am
F-3ASR
byr69228fwk1yq3
10 Nov 21
Automatic shelf registration (foreign)
7:48am
6-K
wix1e7
8 Sep 21
Unaudited Condensed Interim Consolidated Financial Statements
7:58am
6-K
b12oec6 8c5g
1 Jul 21
Current report (foreign)
6:50am
6-K
cd0d6pfl
16 Jun 21
Current report (foreign)
4:03pm
6-K
n46zgmh
20 May 21
Affimed Announces Virtual Annual General Meeting of Shareholders
4:57pm
20-F/A
7a2n7rnhl1vco
21 Apr 21
Annual report (foreign) (amended)
4:40pm
6-K
l489zm7plf 93kjvch
15 Apr 21
Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress
6:57am
6-K
ed8s3mgw
14 Apr 21
Current report (foreign)
4:02pm
6-K
gcddzr3nomle q7xj9x4
9 Apr 21
Current report (foreign)
6:15am
6-K
2s37doyxwp9e7 dezx
10 Mar 21
Affimed Announces Continuation of REDIRECT, a Registration-directed Study of AFM13 in PTCL, after Positive Preplanned Interim Futility Analysis
6:30am
6-K
bln3ia7
15 Jan 21
Current report (foreign)
4:26pm
424B5
81u bk1q3e8zalmdcd8
14 Jan 21
Prospectus supplement for primary offering
5:15pm
424B5
r7ewdibnv9nn6 n1i4g2
13 Jan 21
Prospectus supplement for primary offering
6:05am